Pharmacies and Distributors Express Concerns Over Initial Allocation and Cost Disparities
The highly anticipated obesity drug, 슬롯 사이트 슬롯사이트, has sparked industry complaints just one day after its October 15 launch. Key concerns center on ① limited accessibility and ② significant pricing differences between hospitals and pharmacies.
According to pharmaceutical distributors and pharmacies, issues around supply and pricing surfaced immediately following 슬롯 사이트 슬롯사이트's debut. Developed by Novo Nordisk Korea, 슬롯 사이트 슬롯사이트 (active ingredient: semaglutide) comes in pre-filled pen doses ranging from 0.25 mg to 2.4 mg. As a GLP-1 agonist requiring weekly injections, it enhances insulin secretion and slows digestion, with a longer administration interval compared to its predecessor, Saxenda. Priced at approximately 7.25 per unit, 슬롯 사이트 슬롯사이트 has quickly become a focal point in discussions among healthcare providers and pharmacies.
Complaints about supply policies emerged almost immediately. Initial distribution quantities reportedly fall short of replacing Saxenda, complicating inventory management for distributors. Feedback from distribution channels indicates limited purchasing capacity, where distributors can only replenish stock up to remaining Saxenda inventory levels. For example, if a distributor previously held 2 worth of Saxenda and sold half, they are restricted to a 1.15 슬롯 사이트 슬롯사이트 order until clearing the rest of their Saxenda stock.
Pricing challenges add to the strain: 슬롯 사이트 슬롯사이트’s per-unit cost is nearly five times that of Saxenda. Under current policies, even distributors aiming to purchase 2 in stock can only acquire 슬롯 사이트 슬롯사이트 worth about .23. Additionally, large 슬롯 사이트 슬롯사이트 orders are reportedly causing delays in other product deliveries, disadvantaging distributors who depend on timely, diverse stock.
Concerns have also arisen over allocation preferences. Between October 15 and October 18, 슬롯 사이트 슬롯사이트 will be supplied primarily to hospitals, raising fears of an uneven distribution between hospitals and pharmacies. Some industry insiders suggest that large distributors with substantial pre-orders may drive down pharmacy prices, intensifying market competition.
A representative from a distribution company remarked, “Demand is restricted, and competition is fierce, with initial supplies favoring hospitals. This is causing friction across the industry.” Another distributor noted, “Public interest in 슬롯 사이트 슬롯사이트 was heavily promoted, but misunderstandings over supply consistency and pricing are creating significant challenges for both hospitals and pharmacies.”
The pharmacy community is already experiencing strain. A Seoul pharmacist commented, “There’s disagreement within the community regarding pricing policies. While initial distribution clearly favors hospitals, this imbalance is fueling further tension.”
In response, a representative from Zuellig Pharma stated, “We currently have no comment regarding 슬롯 사이트 슬롯사이트.”